IGM-2323 is a CD20xCD3 IgM bispecific T-cell engager that kills low CD20-expressing and rituximab-resistant B-cell lymphomas

被引：0

作者：

Li, K. ^{[1
]}

Kotturi, M. F. ^{[2
]}

Manlusoc, M. ^{[3
]}

Yun, R. ^{[1
]}

Hinton, P. R. ^{[1
]}

Logronio, K. ^{[2
]}

Baliga, R. ^{[4
]}

Hernandez, G. ^{[5
]}

Sinclair, A. M. ^{[3
]}

Carroll, S. F. ^{[2
]}

Godfrey, W. R. ^{[6
]}

Keyt, B. A. ^{[7
]}

机构：

[1] IGM Biosci, Antibody Discovery, Mountain View, CA USA

[2] IGM Biosci, Preclin Sci, Mountain View, CA USA

[3] IGM Biosci, Immunooncol, Mountain View, CA USA

[4] IGM Biosci, Discovery Biol, Mountain View, CA USA

[5] IGM Biosci, Clin Biomarkers, Mountain View, CA USA

[6] IGM Biosci, Clin Dev Clin Stats & Regulatory, Mountain View, CA USA

[7] IGM Biosci, Res & Dev, Mountain View, CA USA

来源：

ANNALS OF ONCOLOGY | 2021年 / 32卷

关键词：

D O I：

10.1016/j.annonc.2021.08.134

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

841P

引用

页码：S778 / S779

页数：2

共 50 条

[21] Igm-2644, a Novel CD38xCD3 Bispecific IgM T Cell Engager Demonstrates Potent Efficacy on Myeloma Cells with an Improved Preclinical Safety Profile
Li, Keyu
Yun, Rui
Chai, Min
Yakkundi, Poonam
Rosete, Rodnie
Li, Gene
Liu, Liqin
Ng, Dean
Hinton, Paul R.
Kotturi, Maya F.
Sinclair, Angus M.
Carroll, Stephen F.
Muchhal, Umesh
Keyt, Bruce A.
BLOOD, 2022, 140 : 6010 - 6011
[22] Bi20, a novel trifunctional bispecific antibody (CD20xCD3), mediates efficient killing of B-cell lymphoma cells in vitro by activation of T cells and CD14+-accessory cells.
Faltin, M
Stanglmaier, M
Lindhofer, H
BLOOD, 2002, 100 (11) : 575A - 575A
[23] In vitro comparison of CD20xCD3 biosimilar antibodies against diffuse large B-cell lymphoma (DLBCL) cell lines with different levels of expression of CD20
Bray, Joshua S.
Thomas, Gethin R.
Smith, Victoria M.
Wright, Adam
Jayne, Sandrine
Dyer, Martin J. S.
Walter, Harriet S.
BRITISH JOURNAL OF HAEMATOLOGY, 2025,
[24] Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class IgM Based Bispecific Antibody Igm2323 (anti-CD20 x anti-CD3) in Patients with Advanced B-Cell Malignancies
Budde, Elizabeth
Gopal, Ajay K.
Flinn, Ian W.
Nastoupil, Loretta J.
Gordon, Michael S.
Pang, Ching-Fai
Keyt, Bruce
Carroll, Steve
Leabman, Maya
Hernandez, Genevive
Sison, Iris
Chen, Daniel
Godfrey, Wayne
Armand, Philippe
BLOOD, 2020, 136
[25] Modulation of CD20 expression in B-cell lymphomas treated with rituximab.
Seliem, RM
Freeman, JK
Hasserjian, RP
BLOOD, 2002, 100 (11) : 311B - 311B
[26] Treatment of CD20+ B-cell cutaneous lymphomas using intralesional rituximab
Marco, Ardigo
de Felice, Catia
Berardesca, Enzo
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2009, 60 (03) : AB7 - AB7
[27] IGM-2644, a CD38xCD3 bispecific IgM T cell engager, shows enhanced anti-tumor activity compared to daratumumab in preclinical models of multiple myeloma
Hart, Kevin C.
Santos, Daniel
Li, Keyu
Yun, Rui
Chai, Min
Kabai, Andras
Li, Gene
Yakkundi, Poonam
Funke, Roel P.
Guan, Yinghui
Manley, Thomas
Liu, Liqin
Sinclair, Angus M.
Candia, Albert F.
Keyt, Bruce
Kotturi, Maya F.
CANCER RESEARCH, 2024, 84 (06)
[28] CD20xCD3 Bispecific Antibodies As Standard of Care (SOC) for Relapse/Refractory (R/R) Large B-Cell Lymphoma (LBCL)- a Multicenter Retrospective Study
Dong, Ning
Khadka, Sushmita
Sandoval-Sus, Jose
Rondon, Carlos Silva
Perez, Ariel
Al Sagheer, Tiba
Iqbal, Madiha
Alderuccio, Juan Pablo
Arocho, Cristian Rodriguez
Kareem, Syeda Saba
Jain, Michael D.
Chavez, Julio C.
BLOOD, 2024, 144 : 3091 - 3092
[29] CD13 expression by IGM-producing low grade B-cell lymphomas
Park, SI
Bell, J
Mann, KP
Holden, JT
MODERN PATHOLOGY, 2005, 18 : 245A - 245A
[30] CD13 expression by IGM-producing low grade B-cell lymphomas
Park, SJ
Bell, J
Mann, KP
Holden, JT
LABORATORY INVESTIGATION, 2005, 85 : 245A - 245A

← 1 2 3 4 5 →